<http://webisa.webdatacommons.org/266627478>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/266627478>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<ftc.gov> .
<http://webisa.webdatacommons.org/prov/424431655>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/266627478> .
<http://webisa.webdatacommons.org/prov/421681647>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/266627478> .
<http://webisa.webdatacommons.org/266627478>	<http://www.w3.org/ns/prov#value>	"In CMO Distribution Centers of America, Docket No. C-3942 (consent order issued on May 16, 2000), the Commission complaint alleged that the respondents made unsubstantiated claims that CMO??? (cetylmyristoleate) capsules would regulate and normalize the immune system, cure arthritis and reverse the effects of the disease, and be effective in treating other conditions such as asthma and cancer; and" .